ASLAN Pharmaceuticals to Participate in Jefferies London Healthcare Conference

SAN MATEO, Calif. and SINGAPORE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, and Mr Stephen Doyle, CBO will be participating in one-on-one meetings at the Jefferies London Healthcare Conference from November 15 to 17, 2022. The conference will be held in-person at the Waldorf Hilton hotel in London.

Please contact your Jefferies representative to request a one-on-one meeting with management.   

About ASLAN Pharmaceutical

ASLAN Pharmaceuticals (Nasdaq: ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and farudodstat, a potent oral inhibitor of the enzyme DHODH, in autoimmune disease. ASLAN has a team in California and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn.

Media and IR contacts

Emma Thompson Spurwing Communications Tel: +65 6206 7350 Email: ASLAN@spurwingcomms.com

Ashley R. Robinson LifeSci Advisors, LLC Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com